Edition:
United Kingdom

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

0.65USD
22 Jul 2019
Change (% chg)

-- (--)
Prev Close
$0.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,409
52-wk High
$2.76
52-wk Low
$0.47

Latest Key Developments (Source: Significant Developments)

Bellerophon To Present Additional Data From Cohort 1 Of Ongoing Phase 2/3 Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease
Monday, 13 May 2019 

May 13 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON TO PRESENT ADDITIONAL DATA FROM COHORT 1 OF ONGOING PHASE 2/3 STUDY OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AT AMERICAN THORACIC SOCIETY 115TH INTERNATIONAL CONFERENCE.BELLEROPHON THERAPEUTICS INC - RESULTS TO BE PRESENTED IN LATE-BREAKING ABSTRACT AS AN ORAL PRESENTATION.BELLEROPHON THERAPEUTICS INC - COMPANY WILL ALSO PRESENT A CORPORATE OVERVIEW AND UPDATE ON ITS PH-ILD PROGRAM AT RESPIRATORY INNOVATION SUMMIT.BELLEROPHON THERAPEUTICS INC - OVERALL ACTIVITY IMPROVED BY 12% (0% CHANGE ON INO VERSUS. 12% DECREASE ON PLACEBO; P=0.05).BELLEROPHON THERAPEUTICS INC - NT-PROBNP IMPROVED BY 27% (15% INCREASE ON INO VERSUS. 42% INCREASE ON PLACEBO).BELLEROPHON THERAPEUTICS INC - BELLEROPHON ALSO EXPECTS TO INITIATE COHORT 3 IN SECOND HALF OF 2019.  Full Article

Bellerophon Announces Top-Line Results From Cohort 1 Of Inopulse Phase 2B Clinical Trial
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON ANNOUNCES TOP-LINE RESULTS FROM COHORT 1 OF THE INOPULSE® PHASE 2B CLINICAL TRIAL FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE.BELLEROPHON THERAPEUTICS INC - INO WAS WELL-TOLERATED WITH NO SAFETY CONCERNS.BELLEROPHON THERAPEUTICS - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MULTIPLE CLINICALLY MEANINGFUL ACTIVITY PARAMETERS WERE OBSERVED.  Full Article

Bellerophon Therapeutics Q3 Earnings Per Share $0.19
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.19.  Full Article

Bellerophon Therapeutics Inc - Qtrly reports loss per share at $0.10
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.10.BELLEROPHON - ABILITY TO ACCESS FUNDING IS LIKELY TO BE INFLUENCED BY RESULTS OF ONGOING PHASE 2B TRIAL OF INOPULSE FOR PH-ILD.BELLEROPHON SAYS ABILITY TO ACCESS FUNDING IN ANY FORM IS NOT ASSURED.  Full Article

Bellerophon Therapeutics Inc Files For Mixed Shelf Of Up To $100 mln
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING.  Full Article

Bellerophon Q4 Loss Per Share $0.44
Thursday, 15 Mar 2018 

March 15 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.44.  Full Article

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article